Trans4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phen yl]methyl] (2-methyl-2H-tetrazol-5-yl) amino]-2,3,4,5-tetrahydro-7,9-dimethyl1H-1-benzazepin-1-yl]methyl]-cyclohex anecarboxylic acid

Details for Australian Patent Application No. 2010266537 (hide)

Owner Eli Lilly and Company

Inventors Chen, Xinchao; Frank, Scott Alan; Remick, David Michael; Pedersen, Steven Wayne

Agent Spruson & Ferguson

Pub. Number AU-A-2010266537

PCT Pub. Number WO2011/002696

Priority 61/221,708 30.06.09 US

Filing date 28 June 2010

Wipo publication date 6 January 2011

International Classifications

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

2 February 2012 PCT application entered the National Phase

  PCT publication WO2011/002696 Priority application(s): WO2011/002696

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010266539-Pharmaceutical ophthalmological liquid compositions containing propionic acid derivatives as a preservative

2010266535-Analyte monitoring device and methods of use